HIGHBuilt-inPipeline
EB613
“10-K Item 1A: 'our internal resources are currently focused on the development of EB613 and further development of our N-Tab® platform'”
ENTX · Concentration risk · 10-K extracted
Entera Bio (ENTX) concentration risks
Updated
The most significant concentration Entera Bio discloses is EB613, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Entera Bio’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 1 disclosed concentration
HIGH1
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-08-30Entera Bio's concentration profile is dominated by a single, high-share structural exposure: the company discloses that its internal resources are currently focused on the development of EB613 and further development of its N-Tab platform. This is not a customer, supplier, or geographic dependency in the traditional sense — it is a pipeline concentration, meaning the company's near-term prospects rest disproportionately on the successful advancement of one lead program and its underlying delivery technology rather than a diversified portfolio of candidates. Because this exposure is structural rather than a dependency on any single counterparty, it does not carry the kind of counterparty-risk profile seen in customer or supplier concentration — but it does mean that any clinical, regulatory, or commercial setback specific to EB613 or the N-Tab platform would disproportionately affect the company's outlook, since there is no disclosed second program to diversify that risk. Investors should treat this as the single most important variable in the thesis: with only one disclosed concentration and no other risk factors quantified in the filing, the story for Entera Bio is effectively a bet on this one asset and platform succeeding.
For the engine’s reasoning on ENTX’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Biotechnology
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| ABUS | Arbutus Biopharma Corporation | 1 | 1 | 0 | 2 |
| ABSI | Absci Corporation | 1 | 0 | 0 | 1 |
| ENTX● | Entera Bio Ltd. | 1 | 0 | 0 | 1 |
| ABCL | AbCellera Biologics Inc. | 0 | 0 | 0 | 0 |
| ACHV | Achieve Life Sciences, Inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.